Instil Bio, Inc. (TIL)
$10.5
Live
Insights on Instil Bio, Inc.
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 50.9% return, outperforming this stock by 67.2%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 247.4% return, outperforming this stock by 344.2%
Performance
- $10.45$10.60$10.50
0.48%
Downside
Day's Volatility :1.42%
Upside
0.94%
- $6.07$14.00$10.50
42.19%
Downside
52 Weeks Volatility :56.64%
Upside
25.0%
Returns
| Period | Instil Bio, Inc. | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -9.89% | 1.9% | 0.0% |
6 Months | 2885.28% | 10.7% | 0.0% |
1 Year | -16.32% | 4.6% | -1.1% |
3 Years | -96.83% | 14.2% | -22.1% |
Highlights
Market Capitalization | 69.7M |
Book Value | $34.72 |
Earnings Per Share (EPS) | -24.0 |
Wall Street Target Price | 27.67 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -14.01% |
Return On Equity TTM | -52.96% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 138.0K |
EBITDA | -85.8M |
Diluted Eps TTM | -24.0 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -6.35 |
EPS Estimate Next Year | -9.05 |
EPS Estimate Current Quarter | -2.84 |
EPS Estimate Next Quarter | -2.99 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 163.52%
Technicals Summary
Sell
Neutral
Buy
Instil Bio, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Instil Bio, Inc. | -3.67% | 2885.28% | -16.32% | -96.83% | -97.97% |
 Moderna, Inc. | -2.26% | 35.27% | -21.9% | -39.25% | 318.83% |
 Regeneron Pharmaceuticals, Inc. | -5.59% | 12.81% | 13.84% | 81.04% | 166.5% |
 Novo Nordisk A/s | -0.32% | 31.91% | 50.92% | 247.21% | 431.9% |
 Vertex Pharmaceuticals Incorporated | -2.67% | 9.62% | 21.65% | 86.62% | 134.62% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Instil Bio, Inc. | NA | NA | NA | -6.35 | -0.53 | -0.14 | NA | 34.72 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.9 | 25.9 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.09 | 47.09 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.76 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Instil Bio, Inc. | Buy | $69.7M | -97.97% | NA | 0.0% |
Moderna, Inc. | Buy | $40.0B | 318.83% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.8B | 166.5% | 25.9 | 30.14% |
Novo Nordisk A/s | Buy | $558.9B | 431.9% | 47.09 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.4B | 134.62% | 28.81 | 36.68% |
Institutional Holdings
Curative Ventures V LLC
29.20%Vivo Capital, LLC
9.60%Cpmg Inc
6.32%Cable Car Capital LLC
3.97%Nantahala Capital Management, LLC
3.91%Vanguard Group Inc
2.00%
Corporate Announcements
Instil Bio, Inc. Earnings
Instil Bio, Inc.’s price-to-earnings ratio stands at None
Read More
Company Information
instil bio is a cell therapy company developing tumor infiltrating lymphocytes (til) for the treatment of solid tumor cancers. til are a patient’s own t cells harvested from the patient’s tumor, which are then expanded and reinfused into the patient to target and kill cancer cells. the company is advancing its proprietary manufacturing expertise, technology, and data into clinical trials, including a planned registrational study with its lead candidate and a first-in-human study of its next-generation engineered til. the company is led by world-class cell therapy experts and backed by premier global institutional investors. instil is located in the greater los angeles area with additional manufacturing and research facilities in manchester, uk.
Organization | Instil Bio, Inc. |
Employees | 49 |
CEO | Mr. Bronson Crouch |
Industry | Healthcare |
